Market Overview

UPDATE: Piper Jaffray Raises PT to $32 on AmSurg; Long-Term Outlook Positive

Related AMSG
Earnings Scheduled For August 2, 2016
TeamHealth Management Unfazed By Envision-AmSurg Deal

Piper Jaffray maintained AmSurg (NASDAQ: AMSG) with a Neutral rating and raised the price target from $30.00 to $32.00.

Piper Jaffray commented, "We expect AMSG to trade down on mixed Q4 results and FY13 EPS guidance that was lower than Street estimates. Q4 revenues beat, while EPS missed Street expectations due to higher than expected interest expense relative to our model. While FY13 revenue guidance was fine, EPS was lower than expected. AMSG did see a slight uptick in GI procedures due to colon cancer screening and same-center growth of 3% was better than anticipated. We believe the overall environment remains stable and management noted hospitals are proactively reaching out to the company regarding partnership opportunities, which is a long-term positive."

AmSurg closed at $31.26 on Monday.

Latest Ratings for AMSG

Jun 2016Wells FargoInitiates Coverage onMarket Perform
Apr 2016Mizuho Initiates Coverage onBuy
Jan 2016BarclaysInitiates Coverage onEqual-weight

View More Analyst Ratings for AMSG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (AMSG)

View Comments and Join the Discussion!